Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours.


:Nanoscale polymer carriers have the potential to enhance the therapeutic efficacy of antitumour drugs as they can regulate their release, improve their stability and prolong circulation time by protecting the drug from elimination by phagocytic cells or premature degradation. Moreover, nanoscale polymeric carriers are capable of accumulating in tumour cells and tissues due to enhanced permeability and retention effect or by active targeting bearing ligands designed to recognise overexpressed tumour-associated antigens. The diversity in the polymer structures being studied as drug carriers in cancer therapy allows an optimal solution for a particular drug to be provided regarding its delivery and efficacy, and thus the patient's quality of life. This review is focused on the different types of nanoscale polymer carriers used for the delivery of chemotherapeutic agents and on the factors that affect their cellular uptake and trafficking.


Expert Opin Biol Ther


Cegnar M,Kristl J,Kos J





Has Abstract


2005-12-01 00:00:00












  • Immune alterations in malignant melanoma and current immunotherapy concepts.

    abstract:INTRODUCTION:Malignant melanoma is a highly aggressive, immunogenic tumor that has the ability to modulate the immune system to its own advantage. Patients with melanoma present numerous cellular immune defects and cytokine abnormalities, all leading to suppression of the host anti-tumor immune response. Innovative tre...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Shimanovsky A,Jethava A,Dasanu CA

    更新日期:2013-10-01 00:00:00

  • Regeneration of pancreatic beta-cell mass for the treatment of diabetes.

    abstract:INTRODUCTION:The study of the endocrine compartment of the pancreas (the islets of Langerhans) is of great translational interest, as strategies aimed at restoring its mass could become therapies for glycemic dysregulation in type 1 and 2 diabetes mellitus, drug-related diabetes following diabetogenic therapies or hype...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Domínguez-Bendala J,Inverardi L,Ricordi C

    更新日期:2012-06-01 00:00:00

  • Catalytic DNAzymes: derivations and functions.

    abstract:BACKGROUND:Although catalytic RNA enzymes (CRzs) are naturally occurring in many organisms, their DNA counterparts (CDzs) were developed by in vitro selection/evolution from random sequence libraries. OBJECTIVE:To provide a brief overview of how CDzs have been selected in vitro, and of their properties and functions, ...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Pan W,Clawson GA

    更新日期:2008-08-01 00:00:00

  • Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation.

    abstract:INTRODUCTION:Emerging data suggest that human inducible regulatory T cells (Tr1) produce adenosine and prostaglandin E(2) and that these factors cooperate in mediating immune suppression. AREAS COVERED:Human Tr1 present in human tumors or blood of cancer patients express ectonucleotidases, CD39 and/or CD73, hydrolyze ...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Mandapathil M,Whiteside TL

    更新日期:2011-09-01 00:00:00

  • Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis.

    abstract:INTRODUCTION:Ankylosing spondylitis is the prototype of spondyloarthritis, a chronic inflammatory disease involving mainly the axial skeleton. The treatment strategy was, until now, restricted to NSAIDs and anti-TNF agents. Targeting Interleukin 17 is an emerging option with a currently available biologic agent, secuki...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Wendling D,Verhoeven F,Prati C

    更新日期:2019-01-01 00:00:00

  • Future of tissue engineering in rheumatic diseases.

    abstract::Chronic inflammation during rheumatoid arthritis and degenerative processes during osteoarthritis eventually result in joint destruction. Anti-inflammatory therapies facilitate the inhibition or delay of progressing joint cartilage and bone loss, but do not regenerate these tissues. Surgical procedures are quite unsat...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章


    authors: Ringe J,Häupl T,Sittinger M

    更新日期:2007-03-01 00:00:00

  • IC51 Japanese encephalitis vaccine.

    abstract::Japanese encephalitis is the leading cause of viral encephalitis in Asia. Every year 30,000 - 50,000 cases and 10,000 deaths from Japanese encephalitis are reported, and underreporting has been suggested. No effective antiviral therapy exists to treat this mosquito-borne flavivirus infection. For active immunization v...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Kollaritsch H,Paulke-Korinek M,Dubischar-Kastner K

    更新日期:2009-07-01 00:00:00

  • Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.

    abstract:INTRODUCTION:Wet age-related macular degeneration (AMD) is a potentially blinding eye disease that causes vision loss among individuals > 50 years old. The main goal in the treatment of wet AMD is to inhibit the choroidal neovascularization (CNV). Currently, ranibizumab and aflibercept are two available anti-VEGF drug ...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Yazdi MH,Faramarzi MA,Nikfar S,Falavarjani KG,Abdollahi M

    更新日期:2015-01-01 00:00:00

  • Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications.

    abstract:INTRODUCTION:Crohn's disease (CD) is an inflammatory bowel disease of unknown etiology. However, increasing evidence suggests Mycobacterium avium subspecies paratuberculosis (MAP) as a putative causative agent: 1) MAP is the etiological agent of Johne's disease, a granulomatous enteritis affecting ruminants, which shar...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Savarino E,Bertani L,Ceccarelli L,Bodini G,Zingone F,Buda A,Facchin S,Lorenzon G,Marchi S,Marabotto E,De Bortoli N,Savarino V,Costa F,Blandizzi C

    更新日期:2019-02-01 00:00:00

  • HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure (Biopure Corporation).

    abstract:BACKGROUND:Producing an alternative to human erythrocytes has been one the most exciting dreams of medicine. Hemoglobin-based oxygen carriers (HBOCs) derived from purified human or bovine hemoglobin have been studied for clinical use and one product is currently available in the United States and European Union for vet...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Jahr JS,Moallempour M,Lim JC

    更新日期:2008-09-01 00:00:00

  • Myoblast transplantation for inherited myopathies: a clinical approach.

    abstract::Myoblast transplantation (MT) is an experimental strategy for the potential treatment of myopathies. MT has two properties that make it potentially beneficial: genetic complementation and myogenic potential. Preclinical experiments on monkeys have shown that promising results can be obtained with MT in large muscles o...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Skuk D

    更新日期:2004-12-01 00:00:00

  • Gene and cell therapy for pancreatic cancer.

    abstract:INTRODUCTION:The clinical outcomes of patients with pancreatic cancer are poor, and the limited success of classical chemotherapy underscores the need for new, targeted approaches for this disease. The delivery of genetic material to cells allows for a variety of therapeutic concepts. Engineered agents based on synthet...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Singh HM,Ungerechts G,Tsimberidou AM

    更新日期:2015-04-01 00:00:00

  • Monoclonal antibodies in gastrointestinal cancers.

    abstract:INTRODUCTION:Among gastrointestinal cancers, colorectal and gastric neoplasms are the most frequent. The development of new targeted drugs improved the efficacy of systemic therapy in advanced stages of those malignancies. AREAS COVERED:This review highlights the main biological processes implicated in gastrointestina...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Bronte G,Cicero G,Cusenza S,Galvano A,Musso E,Rizzo S,Sortino G,Roselli M,Bazan V,Fiorentino E,Russo A

    更新日期:2013-06-01 00:00:00

  • Update on B-cell targeted therapies for systemic lupus erythematosus.

    abstract:INTRODUCTION:Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by flares and remission, leading to accrual of organ damage over time as a result of persistent tissue inflammation and treatment-related complications. Novel therapies aiming at better treatment response and fewer adverse ef...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Mok CC

    更新日期:2014-06-01 00:00:00

  • Perspectives in the treatment of multiple myeloma.

    abstract:INTRODUCTION:The development of proteasome inhibitor (PI) and immunomodulatory drugs (IMiDs) and advances in supportive care have considerably changed the treatment paradigm of multiple myeloma (MM) and significantly improved survival. Nevertheless, almost all patients show disease relapse and develop drug resistance. ...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Gentile M,Recchia AG,Mazzone C,Lucia E,Vigna E,Morabito F

    更新日期:2013-06-01 00:00:00

  • Human stem cell grafts as therapies for motor neuron disease.

    abstract::Stem cell transplantation, a widely accepted therapeutic approach to diseases of modular organs such as the heart and the endocrine pancreas, remains a controversial option for the nervous system. However, historical advances in the 1990s on key aspects of neural plasticity and the appreciation of the selective vulner...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Koliatsos VE,Xu L,Yan J

    更新日期:2008-02-01 00:00:00

  • Tocilizumab for treating juvenile idiopathic arthritis.

    abstract:INTRODUCTION:Based on the known relevance of IL-6 in juvenile idiopathic arthritis (JIA) pathophysiology, tocilizumab has been investigated and approved for use in the treatment of systemic and polyarticular JIA. Tocilizumab is a humanized monoclonal antibody that inhibits signaling through both membrane bound and solu...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Turnier JL,Brunner HI

    更新日期:2016-01-01 00:00:00

  • Bone tissue engineering: recent advances and promising therapeutic agents.

    abstract::Bone regeneration can be accomplished with growth factors, cells and delivery systems. This review is a summary of these components that may be used for tissue regeneration. Support for the potential therapeutic applications of transcription factors in bone tissue engineering will also be discussed. ...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Jadlowiec JA,Celil AB,Hollinger JO

    更新日期:2003-06-01 00:00:00

  • A comparison of human natural monoclonal antibodies and aptamer conjugates for promotion of CNS remyelination: where are we now and what comes next?

    abstract:INTRODUCTION:Multiple sclerosis (MS) is a chronic and progressive inflammatory demyelinating disease of the human central nervous system (CNS) and is the most common disabling neurological condition in young adults, resulting in severe neurological defects. No curative or long-term progression-inhibiting therapy has ye...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Perwein MK,Smestad JA,Warrington AE,Heider RM,Kaczor MW,Maher LJ 3rd,Wootla B,Kunbaz A,Rodriguez M

    更新日期:2018-05-01 00:00:00

  • Facing the future: challenges and opportunities in adoptive T cell therapy in cancer.

    abstract:INTRODUCTION:In recent years, immunotherapy for the treatment of solid cancer has emerged as a promising therapeutic alternative. Adoptive cell therapy (ACT), especially T cell-based, has been found to cause tumor regression and even cure in a percentage of treated patients. Checkpoint inhibitors further underscore the...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Magalhaes I,Carvalho-Queiroz C,Hartana CA,Kaiser A,Lukic A,Mints M,Nilsson O,Grönlund H,Mattsson J,Berglund S

    更新日期:2019-08-01 00:00:00

  • Fibrin sealants: surgical hemostat, sealant and adhesive.

    abstract:INTRODUCTION:Fibrin sealants (FS) have been approved for use in the United States since 1998. Since approval, they have been used in a wide variety of clinical settings and new products continue to be introduced. AREAS COVERED:This review covers the literature supporting the USA FDA-approved indications for FS product...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Mandell SP,Gibran NS

    更新日期:2014-06-01 00:00:00

  • The future of immunotherapy for sarcoma.

    abstract:INTRODUCTION:The use of immunotherapeutic challenges for sarcoma has a long history. Despite the existence of objective responses, immunotherapy has been overshadowed by the results of chemotherapy, especially for osteosarcoma. However, the prognosis for non-responders to chemotherapy is still poor and immunotherapy is...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Tsukahara T,Emori M,Murata K,Mizushima E,Shibayama Y,Kubo T,Kanaseki T,Hirohashi Y,Yamashita T,Sato N,Torigoe T

    更新日期:2016-08-01 00:00:00

  • Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.

    abstract:INTRODUCTION:About 99% of all autologous transplants are now performed with blood stem cells. G-CSF alone or combined with chemotherapy have been used to mobilize CD34(+) cells. Plerixafor is a novel drug used for mobilization purposes. AREAS COVERED:We have evaluated recent data in regard to plerixafor use in predict...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Jantunen E,Varmavuo V

    更新日期:2014-06-01 00:00:00

  • Nanotechnology and medicine.

    abstract::Nanotechnology, or systems/device manufacture at the molecular level, is a multidisciplinary scientific field undergoing explosive development. The genesis of nanotechnology can be traced to the promise of revolutionary advances across medicine, communications, genomics and robotics. On the surface, miniaturisation pr...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Emerich DF,Thanos CG

    更新日期:2003-07-01 00:00:00

  • Antisense oligonucleotides in the treatment of bladder cancer.

    abstract::This review examines the role that antisense oligonucleotides play in the treatment of superficial and muscle-invasive bladder cancer. The unique environment of the urinary bladder allows intravesical instillation of antisense oligonucleotides, and researchers have already demonstrated uptake of antisense oligonucleot...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Glackin AJ,Gray SB,Johnston SR,Duggan BJ,Williamson KE

    更新日期:2005-01-01 00:00:00

  • Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.

    abstract:INTRODUCTION:Treatment options for patients suffering from neuromyelitis optica spectrum disorders (NMOSD) so far have relied on off-label and empiric drugs. The first drug for the therapy of anti-aquaporin-4 (AQP4) antibody-seropositive NMOSD patients has been approved in 2019: the C5 complement inhibitor eculizumab. ...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章


    authors: Duchow A,Paul F,Bellmann-Strobl J

    更新日期:2020-09-01 00:00:00

  • The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis.

    abstract:BACKGROUND:Contrast enhancing lesions (CELs) in MRI represent inflammatory events in multiple sclerosis (MS). IFN-beta-1b decreases the formation of CELs. However, the ability of IFN-beta-1b to reduce the size of CELs arising during therapy has not been extensively investigated. METHODS:Thirty patients with relapsing-...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章


    authors: Gaindh D,Jeffries N,Ohayon J,Richert ND,Pellicano C,Frank JA,McFarland H,Bagnato F

    更新日期:2008-12-01 00:00:00

  • Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?

    abstract:INTRODUCTION:Two humanized monoclonal antibodies, bapineuzumab and solanezumab, directed against the N terminus and mid-region of β-amyloid (Aβ), respectively, were recently tested in large, long-term Phase III trials in patients with mild-to-moderate Alzheimer's disease (AD). AREAS COVERED:This review discusses curre...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Panza F,Solfrizzi V,Imbimbo BP,Logroscino G

    更新日期:2014-10-01 00:00:00

  • Necitumumab for non-small cell lung cancer.

    abstract:INTRODUCTION:Targeting the EGFR pathway is a rational approach to treat patients with advanced NSCLC. Necitumumab, a second-generation recombinant fully human immunoglobulin G1 monoclonal antibody directed against EGFR, has recently been assessed in combination with first-line cisplatin-based chemotherapy. AREAS COVER...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章,评审


    authors: Greillier L,Tomasini P,Barlesi F

    更新日期:2015-01-01 00:00:00

  • Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes.

    abstract:OBJECTIVE:Due to its low price, bevacizumab, which binds vascular endothelial growth factor, is currently used off-label for the treatment of over 50 different eye diseases and has been adopted worldwide despite the absence of serious preclinical data. This study examines the effects of intravitreal bevacizumab on monk...

    journal_title:Expert opinion on biological therapy

    pub_type: 杂志文章


    authors: Schraermeyer U,Julien S

    更新日期:2013-02-01 00:00:00